Evaluation of patients with suspected systemic infection, in particular infection caused by gram-negative bacteria
TNF
TNF-Alpha
Cytokine
Plasma EDTA
Collection Container/Tube: Lavender top (EDTA)
Submission Container/Tube: Plastic vial
Specimen Volume: 0.5 mL
Collection Instructions:
1. Immediately after specimen collection, place the tube on wet ice.
2. Centrifuge at 1500 x g for 10 minutes and aliquot plasma into plastic vial.
3. Freeze specimen within 30 minutes.
0.3 mL
Gross hemolysis | OK |
Gross lipemia | OK |
Gross icterus | OK |
Heat-treated specimen | Reject |
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Plasma EDTA | Frozen (preferred) | 21 days | |
Refrigerated | 24 hours |
Evaluation of patients with suspected systemic infection, in particular infection caused by gram-negative bacteria
Due to the significant proinflammatory and immunoregulatory functions of TNF-alpha, and the wide distribution of TNFRs, the deregulation TNF-alpha is associated with the development of several immunologic disorders and prediction of disease outcomes.(1-7) Indeed, elevated levels of TNF-alpha in serum or plasma levels have been able to predict severity in some infectious diseases such as sepsis in bacterial infections or poor outcomes in coronavirus 2019 infections.(6) In addition, TNF-alpha has been implicated in post-transplant reactions, pathological mechanisms in certain autoimmune diseases (eg, rheumatoid arthritis, inflammatory bowel disease, ankylosing spondylitis), and cancers.(1-5,7) With the FDA approval of biologic and biosimilar therapies targeting TNF-alpha in patients with these diseases, it is likely that measurement of TNF-alpha levels may be useful in management of treatment response.(4-9)
< or =2.8 pg/mL
5. Friedrich M, Pohin M, Powrie F: Cytokine networks in the pathophysiology of inflammatory bowel disease. Immunity. 2019;50:992-1006
6. Wilson JG, Simpson LJ, Ferreira AM, et al: Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis. JCI Insight. 2020;5(17):e140289
The tumor necrosis factor (TNF)-alpha cytokine assay measures human cytokines in a 96-well spotted plate. The assay employs a sandwich immunoassay format where capture antibodies are coated on a single spot on the bottom of each well. Diluted samples, calibrators, and controls are added and to the plate. If present, TNF-alpha will bind to the capture antibodies. After incubation, a solution containing detection antibodies conjugated with electrochemiluminescent labels is added. After a final incubation, a buffer is added that creates the appropriate chemical environment for electrochemiluminescence. The plate is then read on the MSD QuickPlex SQ120. The machine applies a voltage that causes bound labels to emit measurable light. The MSD QuickPlex SQ120 measures the intensity of emitted light and correlates it to a set of standards of known quantity via a 4-point logistics curve fitting method.(Package Insert: Human TNF-alpha V-plex. Mesoscale Discovery; 2014)
Thursday
This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.
83520
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
TNFA | Tumor Necrosis Factor, P | 3074-2 |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
63022 | TNF, P | 3074-2 |
Change Type | Effective Date |
---|---|
Test Status - Test Resumed | 2023-01-26 |
Test Status - Test Down | 2023-01-04 |
Test Status - Test Delay | 2022-12-23 |